Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vaxart reports solid Q1 earnings, progresses in vaccine development

Vaxart's Q1 2024 performance reflects financial stability and progress in vaccine development, particularly with positive Phase I trial results for their norovirus vaccine.
While the company faces challenges in funding, manufacturing, and program prioritization, opportunities lie in advancing COVID-19 vaccine trials and regulatory engagements.
By addressing concerns and leveraging opportunities effectively, Vaxart can strengthen its position in the vaccine market and drive future growth and innovation.

Vaxart reports strong Q3 revenue, advances in COVID and norovirus

Vaxart's Q3 2024 earnings call highlighted revenue from government contracts, progress in COVID, norovirus, and HPV programs, and promising trial data.
The company faces challenges in study enrollment, resource allocation, and regulatory compliance but remains open to collaborations and global vaccine development.
With a cash runway into 2026, Vaxart is well-positioned to leverage market demand for their oral pill vaccine candidates and drive future growth.
Strong performance, constructive FDA feedback, and market opportunities position Vaxart for continued success in vaccine development and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.

Vir Biotechnology

They'll be later to market than rivals. But if their product candidates are stronger, investors may reap rewards.

2 Ultra-Risky Coronavirus Stocks That Could Make You Filthy Rich

Citi Trends

Louisiana-Pacific

Nautilus

Novavax

Ultra Clean

Unisys

VirnetX

XBiotech

These are the small cap stocks with the best value, fastest growth, and most momentum for December 2020.

Top Small Cap Stocks for December 2020

Moderna

Here's what makes these coronavirus-focused biotechs stand out.

3 COVID Vaccine Stocks That Could Be Millionaire-Makers

Inovio Pharmaceuticals

Telesis Bio Inc

In the race to develop a coronavirus vaccine, Pfizer and its partner BioNTech have a lead, closely followed by Moderna. However, four other biotechs, NVAX, TBIO, INO and VXRT, still hold potential to gain from their vaccine development efforts.

4 Biotechs Likely to Gain on Coronavirus Vaccine Efforts

Aprea Therapeutics

Viking Therapeutics

Aprea Therapeutics, Viking Therapeutics, and Vaxart could all generate life-changing returns for early shareholders.

3 Stocks with Jaw-Dropping Growth Potential

Title: An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus

Vaxart Hosting Key Opinion Leader Panel Call for Investors

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that management will be participating in two upcoming virtual investor conferences and invites investors to participate by webcast. Please see additional details below:

Vaxart Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference

Enrollment in Phase 1 for Oral COVID-19 Vaccine Trial Completed

Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update

The tiny biotech's COVID-19 vaccine has generated excitement because it's a pill instead of a shot, which gives it a number of important advantages.

Vaxart Reports More Positive Data From Animal Testing of Its Coronavirus Vaccine Candidate

Vaxart (VXRT) is getting a boost to VXRT stock on Thursday after releasing positive news concerning its vaccine for the novel coronavirus. The post VXRT Stock News: Vaxart Shares Surge on Promising COVID-19 Vaccine News appeared first on InvestorPlace.

VXRT Stock News: Vaxart Shares Surge on Promising COVID-19 Vaccine News

Can-Fite BioPharma Ltd.

Five Prime Therapeutics

GT Biopharma Inc

InflaRx

Tonix Pharmaceuticals Hld

vTv Therapeutics

With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 Biotech Penny Stocks Worth a Gamble appeared first on InvestorPlace.

7 Biotech Penny Stocks Worth a Gamble

These three pre-revenue COVID-19 vaccine stocks took a beating last month.

Why Inovio Pharmaceuticals, Novavax, and Vaxart Crashed in October

These companies won't cross the finish line first. But if and when they do, they're sure to grab market share.

These 2 Coronavirus Vaccine Stocks Could Be Game-Changers

These companies aren't about to win the coronavirus vaccine race, but their competitors probably will.

Avoid These 2 Coronavirus Innovator Stocks in November

During Vaxart's (VXRT) impending third-quarter conference call, investors will keep tabs of its progress with its oral COVID-19 vaccine candidate VXA-CoV2-1.

Vaxart (VXRT) to Report Q3 Earnings: What's in the Cards?

Teladoc

These two companies are upending the norms of their domains.

Disruptor Alert: These 2 Companies Are Changing Healthcare

Arcturus Therapeutics

It's still really early for these two biotech stocks. But their experimental COVID-19 vaccines have tremendous potential.

2 Under-the-Radar Coronavirus Vaccine Stocks to Watch

Big Lots

Co-Diagnostics

Textainer Group Holdings Limited

TTM Technologies

These are the small cap stocks with the best value, fastest growth, and most momentum for November 2020.

Top Small Cap Stocks for November 2020

Los Angeles, California--(Newsfile Corp. - October 23, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Vaxart, Inc. ("Vaxart" or "the Company") (NASDAQ: VXRT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 25, 2020 and July 25, 2020, inclusive...

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vaxart, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - October 23, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Vaxart, Inc. ("Vaxart " or the "Company") (NASDAQ: VXRT) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Vaxart securities between June 25, 2020 and July 25, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by...

VXRT Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Vaxart, Inc. Investors With Losses Exceeding $500K of Class Action and Lead Plaintiff Deadline: October 23, 2020

Vaxart, an oral tablet vaccine developer, has initiated and dosed the first participants in their phase 1 trial for COVID-19. Although later in development, Vaxart's oral tablet vaccine presents significant advantages in manufacture, distribution and ease-of- administration that may contribute to a much more successful vaccination campaign, if successfully developed.

Vaxart: A Strong Buy For Their Oral Tablet Covid-19 Vaccine

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Vaxart To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 23, 2020) -  If you suffered losses exceeding $50,000 investing in Vaxart stock or options between June 25, 2020 to July 25, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/VXRT or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Vaxart Shareholder Alert

New York, New York--(Newsfile Corp. - October 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Vaxart, Inc. ("Vaxart") (NASDAQ: VXRT) between June 25, 2020 and July 25, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Northern District of California. To get more information...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Vaxart, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 23, 2020 - VXRT

NEW YORK, Oct. 22, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Vaxart, Inc. (NASDAQ: VXRT) between June 25, 2020 to July 25, 2020, inclusive (the "Class Period"), of the important October 23, 2020 lead plaintiff deadline...

VXRT FINAL DEADLINE NOTICE: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Reminds Vaxart, Inc. Investors of Important Friday Deadline in Securities Class Action - VXRT

New York, New York--(Newsfile Corp. - October 22, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Vaxart, Inc. (NASDAQ: VXRT) alleging that the Company violated federal securities laws.Class Period: June 25, 2020 and July 25, 2020Lead Plaintiff Deadline: October 23, 2020Learn more about your recoverable losses in VXRT:

VXRT ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 23, 2020 in the Class Action Filed on Behalf of Vaxart, Inc. Limited Shareholders

News for Vaxart Stock (VXRT)